Estimation of Eligibility for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Associated Costs Based on the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk): Insights From the
| Image |  |
|---|---|
| Description | scientific article published on 2 May 2017 |
| Author/s |
author: Khurram Nasir Christie M. Ballantyne Salim S. Virani Erin D. Michos |
| Publication date | May 2, 2017 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |